Search results
Results from the WOW.Com Content Network
Ceftaroline fosamil is a prodrug of ceftaroline. It is active against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria. It retains some activity of later-generation cephalosporins having broad-spectrum activity against Gram-negative bacteria, but its effectiveness is relatively much weaker.
Ceftaroline has low water solubility but this problem was overcome by attaching a N-phosphonoamino group to the molecule making the intravenous prodrug ceftaroline fosamil. The prodrug is dephosphorylated in plasma to form active ceftaroline. [28] 5th generation cephalosporins: A) ceftaroline fosamil (prodrug); B) ceftobiprole medocaril (prodrug)
Linezolid is a member of the oxazolidinone class of medications. [10] Linezolid was discovered in the mid-1990s, and was approved for commercial use in 2000. [16] [17] It is on the World Health Organization's List of Essential Medicines. [18] The World Health Organization classifies linezolid as critically important for human medicine. [19]
In 2027, negotiated prices will go into effect for 15 more drugs, followed by another 15 drugs in 2028 and 20 more in each subsequent year should the program remain in place.
For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...
Talk about a tale of two cities. A new report calls New York one of the best cities in the country for an active lifestyle — while a spot right across the Hudson River ranks as one of the worst ...
Ceftobiprole has shown in vitro antimicrobial activity against a broad range of Gram-positive and Gram-negative pathogens. Among the Gram-positive pathogens, ceftobiprole has demonstrated good in vitro activity against methicillin-resistant Staphylococcus aureus, methicillin-susceptible Staphylococcus aureus and coagulase-negative staphylococci, as well as against strains of methicillin ...
A 2004 study showed that people in the United States with S. aureus infection had, on average, three times the length of hospital stay (14.3 vs. 4.5 days), incurred three times the total cost ($48,824 vs. $14,141), and experienced five times the risk of in-hospital death (11.2% vs 2.3%) than people without this infection. [123]